4.7 Article

The FSHD2 Gene SMCHD1 Is a Modifier of Disease Severity in Families Affected by FSHD1

Journal

AMERICAN JOURNAL OF HUMAN GENETICS
Volume 93, Issue 4, Pages 744-751

Publisher

CELL PRESS
DOI: 10.1016/j.ajhg.2013.08.004

Keywords

-

Funding

  1. US National Institutes of Health (NIH) (National Institute of Neurological Disorders and Stroke [NINDS]) [P01NS069539]
  2. US National Institutes of Health (NIH) (National Institute of Arthritis and Musculoskeletal and Skin Diseases [NIAMS]) [R01AR045203]
  3. Muscular Dystrophy Association (MDA) [217596]
  4. Fields Center for FSHD Research
  5. Geraldi Norton and Eklund family foundation
  6. FSH Society
  7. Friends of FSH Research
  8. French Association Against Myopathies (AFM)
  9. European Union [7 2012-305121]
  10. Prinses Beatrix Spierfonds [W.OR-12-20]
  11. Stichting FSHD

Ask authors/readers for more resources

Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is caused by contraction of the D4Z4 repeat array on chromosome 4 to a size of 1-10 units. The residual number of D4Z4 units inversely correlates with clinical severity, but significant clinical variability exists. Each unit contains a copy of the DUX4 retrogene. Repeat contractions are associated with changes in D4Z4 chromatin structure that increase the likelihood of DUX4 expression in skeletal muscle, but only when the repeat resides in a genetic background that contains a DUX4 polyadenylation signal. Mutations in the structural maintenance of chromosomes flexible hinge domain containing 1 (SMCHD1) gene, encoding a chromatin modifier of D4Z4, also result in the increased likelihood of DUX4 expression in individuals with a rare form of FSHD (FSHD2). Because SMCHD1 directly binds to D4Z4 and suppresses somatic expression of DUX4, we hypothesized that SMCHD1 may act as a genetic modifier in FSHD1. We describe three unrelated individuals with FSHD1 presenting an unusual high clinical severity based on their upper-sized FSHD1 repeat array of nine units. Each of these individuals also carries a mutation in the SMCHD1 gene. Familial carriers of the FSHD1 allele without the SMCHD1 mutation were only mildly affected, suggesting a modifier effect of the SMCHD1 mutation. Knocking down SMCHD1 in FSHD1 myotubes increased DUX4 expression, lending molecular support to a modifier role for SMCBD1 in FSHD1. We conclude that FSHD1 and FSHD2 share a common pathophysiological pathway in which the PSHD2 gene can act as modifier for disease severity in families affected by FSHD1.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available